Skip to main content

IL-23

    RT @MeralElRamahiMD: ⭐️Ustekinumab+MTX vs. UST+PBO in PsA?

    ➡️Additional MTX has no positive impact on UST effic
    ⭐️Ustekinumab+MTX vs. UST+PBO in PsA? ➡️Additional MTX has no positive impact on UST efficacy for arthritis, enthesitis, dactylitis, skin, QoL, & function. *️⃣Thus, no evident to add or maintain ongoing MTX when starting UST Late-Breaking Poster#12. #ACR21 @RheumNow #ACRBest https://t.co/k96PPUtwct
    RT @Janetbirdope: #Guselkimab Better than #ustekinumab for skin& MSK. #Ixekizumab beat ustekinumab for skin. #usteki
    2 years ago
    #Guselkimab Better than #ustekinumab for skin& MSK. #Ixekizumab beat ustekinumab for skin. #ustekinumab loses throne in #psoriasis and #psoriatic arthritis except maybe if concomitant inflammatory bowel disease post TNFi? Rapidly evolving PsA Rx. Abst#1773 #ACR21 @RheumNow https://t.co/Dkf2DFFsSK
    RT @doctorRBC: Methotrexate did not improve Ustekinumab efficacy in tx of PsA
    ⭐️Addition of MTX did not improve dact
    Methotrexate did not improve Ustekinumab efficacy in tx of PsA ⭐️Addition of MTX did not improve dactylitis, enthesitis, skin, QoL or function #ACR21 #ACRBest @RheumNow Abs#L12 https://t.co/6dxWPNskou https://t.co/BnzH8PfaMV
    RT @doctorRBC: Phase 2 trial of tildrakizumab (IL-23i) for the treatment of PsA showed lower efficacy in pts with metabo
    Phase 2 trial of tildrakizumab (IL-23i) for the treatment of PsA showed lower efficacy in pts with metabolic syndrome compared to those without #ACR21 @RheumNow Abs#1819 https://t.co/GYHbiH9NSW https://t.co/YGcZcITjzj
    RT @DrPetryna: Abst1773 #ACR21 @rheumnow guselkumab outperforms ustekinumab in both msk & skin domains in bio naive
    2 years ago
    Abst1773 #ACR21 @rheumnow guselkumab outperforms ustekinumab in both msk & skin domains in bio naive & bio experienced alike- data from pivotal Phase III trials : at weeks 52 GUS better ACR20, PASI100 in both doses vs Stelara https://t.co/lfddaCJA5O
    RT @RichardPAConway: No benefit to using MTX in combination with ustekinumab in PsA. No difference in efficacy for arthr
    No benefit to using MTX in combination with ustekinumab in PsA. No difference in efficacy for arthritis, enthesitis, dactylitis, skin, QoL or function. Abstr#L12 #ACR21 @RheumNow https://t.co/iojKLqRb06
    RT @RichardPAConway: Individual patient data analysis from RCTs (indirect comparison) of guselkumab vs ustekinumab in Ps
    Individual patient data analysis from RCTs (indirect comparison) of guselkumab vs ustekinumab in PsA. Guselkumab appears superior for joint and skin. Abstr#1773 #ACR21 @RheumNow https://t.co/MTRjXyHoh6
    ×